Login to Your Account



CFDA approves GSK's Cervarix as China's first HPV vaccine

By Cornelia Zou
Staff Writer

Monday, July 18, 2016

HONG KONG – A decade after the U.S. launch, Glaxosmithkline plc's Cervarix vaccine to prevent the human papillomavirus (HPV) is in the home stretch to launch as the first HPV vaccine in Mainland China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription